ATE441634T1 - Chinolinderivate mit insbesondere antiviralen eigenschaften, herstellung und biologische anwendungen davon - Google Patents

Chinolinderivate mit insbesondere antiviralen eigenschaften, herstellung und biologische anwendungen davon

Info

Publication number
ATE441634T1
ATE441634T1 AT98920581T AT98920581T ATE441634T1 AT E441634 T1 ATE441634 T1 AT E441634T1 AT 98920581 T AT98920581 T AT 98920581T AT 98920581 T AT98920581 T AT 98920581T AT E441634 T1 ATE441634 T1 AT E441634T1
Authority
AT
Austria
Prior art keywords
aryl
group
different
alkyl
substituents
Prior art date
Application number
AT98920581T
Other languages
English (en)
Inventor
Khalid Mekouar
Angelo Jean D
Didier Desmaele
Jean-Francois Mouscadet
Frederic Subra
Christian Auclair
Original Assignee
Centre Nat Rech Scient
Roussy Inst Gustave
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Roussy Inst Gustave filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE441634T1 publication Critical patent/ATE441634T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/24Oxygen atoms attached in position 8
    • C07D215/26Alcohols; Ethers thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98920581T 1997-04-08 1998-04-07 Chinolinderivate mit insbesondere antiviralen eigenschaften, herstellung und biologische anwendungen davon ATE441634T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9704289A FR2761687B1 (fr) 1997-04-08 1997-04-08 Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
PCT/FR1998/000701 WO1998045269A1 (fr) 1997-04-08 1998-04-07 Derives de quinoleines en tant qu'inhibiteurs de la vih integrase

Publications (1)

Publication Number Publication Date
ATE441634T1 true ATE441634T1 (de) 2009-09-15

Family

ID=9505648

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98920581T ATE441634T1 (de) 1997-04-08 1998-04-07 Chinolinderivate mit insbesondere antiviralen eigenschaften, herstellung und biologische anwendungen davon

Country Status (12)

Country Link
US (1) US6670377B1 (de)
EP (1) EP0975597B1 (de)
JP (1) JP4697679B2 (de)
AT (1) ATE441634T1 (de)
CA (1) CA2286385C (de)
CY (1) CY1109553T1 (de)
DE (1) DE69841119D1 (de)
DK (1) DK0975597T3 (de)
ES (1) ES2332434T3 (de)
FR (1) FR2761687B1 (de)
PT (1) PT975597E (de)
WO (1) WO1998045269A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2321348A1 (en) * 2000-09-27 2002-03-27 Blaise Magloire N'zemba Aromatic derivatives with hiv integrase inhibitory properties
FR2819507B1 (fr) 2001-01-17 2007-09-28 Inst Rech Developpement Ird Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus
JP3616628B2 (ja) 2001-03-01 2005-02-02 塩野義製薬株式会社 Hivインテグラーゼ阻害活性を有する含窒素芳香族複素環化合物
FR2830863B1 (fr) * 2001-10-12 2004-01-30 Bioalliance Pharma Derives de quinoleine, procede de synthese, et medicaments renfermant ces derives
FR2839646B1 (fr) * 2002-05-17 2008-04-11 Bioalliance Pharma Utilisation de derives de quinoleine a effet anti-integrase et ses applications
ATE404537T1 (de) 2002-08-13 2008-08-15 Shionogi & Co Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung
SK2662004A3 (sk) 2002-11-20 2005-06-02 Japan Tobacco, Inc. Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz
RU2275361C3 (ru) * 2002-11-20 2021-10-01 Джапан Тобакко Инк. Соединение 4-оксохинолина и его применение в качестве ингибитора вич интегразы
US7531554B2 (en) 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
KR100866296B1 (ko) * 2004-05-20 2008-11-11 니뽄 다바코 산교 가부시키가이샤 4―옥소퀴놀린 화합물의 안정한 결정체
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2006129134A1 (en) * 2005-06-01 2006-12-07 Bioalliance Pharma Synergic combinations comprising a styrylquinoline compound and other hiv infection therapeutic agents
ES2531190T3 (es) 2006-03-06 2015-03-11 Japan Tobacco Inc Método para producir un compuesto de 4-oxoquinolina
MX2009013332A (es) 2007-06-08 2010-01-25 Mannkind Corp Inhibidores de ire-1 alfa.
ES2402322T3 (es) * 2007-11-15 2013-04-30 Gilead Sciences, Inc. Inhibidores de la replicación del virus de la inmunodeficiencia humana
ATE541841T1 (de) * 2007-11-15 2012-02-15 Boehringer Ingelheim Int Inhibitoren der replikation des human immunodeficiency virus
ES2463720T3 (es) * 2007-11-16 2014-05-29 Gilead Sciences, Inc. Inhibidores de la replicación del virus de inmunodeficiencia humana
EA019259B1 (ru) * 2007-11-16 2014-02-28 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
EP2149557A1 (de) 2008-07-23 2010-02-03 BioAlliance Pharma Styrylchinoline, Herstellungsverfahren dafür und therapeutische Anwendungen davon
EP2147912A1 (de) 2008-07-23 2010-01-27 BioAlliance Pharma Styrylchinoline, Herstellungsverfahren dafür und therapeutische Anwendungen
EP2147913A1 (de) * 2008-07-23 2010-01-27 BioAlliance Pharma Styrylchinoline, Herstellungsverfahren dafür und therapeutische Anwendungen davon
EP2588455B1 (de) * 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-essigsäure derivate als hiv antivirale verbindungen
US9731001B2 (en) 2011-12-22 2017-08-15 Universite Laval Three-dimensional cavities of dendritic cell immunoreceptor (DCIR), compounds binding thereto and therapeutic applications related to inhibition of human immunodeficiency virus type-1 (HIV-1)
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
CR20210175A (es) 2018-09-18 2021-06-01 Nikang Therapeutics Inc Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59152891A (ja) * 1983-02-18 1984-08-31 Yamada Kagaku Kogyo Kk 発色性記録材料
IE861607L (en) * 1985-06-18 1986-12-18 Bunce Roger A 2-substituted quinolines
EP0219307A3 (de) * 1985-10-16 1987-10-14 Merck Frosst Canada Inc. 2-Substituierte Chinoline
JPS61189988A (ja) * 1986-08-11 1986-08-23 Yamada Kagaku Kogyo Kk 発色性記録材料
JPH01199979A (ja) * 1987-04-07 1989-08-11 Kanebo Ltd 新規キノリンカルボン酸誘導体および該化合物を有効成分とする抗菌剤
EP0318093A3 (de) * 1987-11-25 1990-12-05 Merck Frosst Canada Inc. Diarylchinolindicarbonsäure und ihre Verwendung als Arzneimittel
US5438141A (en) * 1993-05-21 1995-08-01 Merck Frosst Canada, Inc. Heteroaryl and haloaryl quinoline derivatives of cyclopropaneacetic acid as leukotriene antagonists
EP0643045B1 (de) * 1993-09-10 2000-03-08 Novartis AG Chinolin-Verbindungen als Leukotriene Antagonisten
GB9414590D0 (en) * 1994-07-20 1994-09-07 Leo Pharm Prod Ltd Chemical compounds
ES2103180B1 (es) * 1994-08-01 1998-04-01 Menarini Lab Fenilacetamidas con accion antagonista de los leucotrienos.
EP0725063A1 (de) * 1995-02-01 1996-08-07 Ciba-Geigy Ag Chinolin-Derivate
US6310211B1 (en) * 1996-09-10 2001-10-30 Pharmacia & Upjohn Company 8-hydroxy-7-substituted quinolines as anti-viral agents

Also Published As

Publication number Publication date
WO1998045269A1 (fr) 1998-10-15
JP4697679B2 (ja) 2011-06-08
CA2286385C (fr) 2011-02-01
ES2332434T3 (es) 2010-02-04
DE69841119D1 (de) 2009-10-15
JP2001518890A (ja) 2001-10-16
DK0975597T3 (da) 2009-11-02
FR2761687B1 (fr) 2000-09-15
PT975597E (pt) 2010-01-04
EP0975597B1 (de) 2009-09-02
CA2286385A1 (fr) 1998-10-15
CY1109553T1 (el) 2014-08-13
FR2761687A1 (fr) 1998-10-09
EP0975597A1 (de) 2000-02-02
US6670377B1 (en) 2003-12-30

Similar Documents

Publication Publication Date Title
ATE441634T1 (de) Chinolinderivate mit insbesondere antiviralen eigenschaften, herstellung und biologische anwendungen davon
DK0916646T3 (da) Fremgangsmåde til fremstillingen af en substitueret 2,5-diamino-3-hydroxyhexan
WO2003068750A1 (en) Jnk inhibitor
NO20033385D0 (no) Fuserte heterocykliske forbindelser
HRP20010573B1 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
MX9504349A (es) Derivados de aroilpiperidina.
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
CA2360943A1 (en) N2-phenylamidine derivatives
EP1206935A4 (de) Th2 differenzierungshemmer
EP0713870A4 (de) Neue kondensierte indan-derivate und ihre pharmazeutisch verträglichen salze
DE60001218D1 (de) [1,8]-naphthyridinderivate derivate mit antiviraler wirkung
EP1020452A4 (de) Benzimidazolderivate
EP0751145A3 (de) HIV-Protease Inhibitoren
EP1422225A4 (de) Benzoisoselenazolderivate mit entzündungshemmender, antiviraler und antithrombotischer wirkung und deren verwendungen
NO20002589D0 (no) Bifenylamidinderivater
MA27065A1 (fr) Composes inhibant la liberation des cytokines inflammatoires.
WO2005061475A3 (en) Ornithine derivatives as prostaglandin e2 agonists or antagonists
NO973213L (no) Nye 2-(1H)-quinolinforbindelser, fremgangsmåter ved fremstilling av slike samt farmasöytiske sammensetninger omfattende disse
EP1568697A4 (de) 1,3-benzothiazinonderivate, deren herstellungsverfahren und verwendung
ATE342260T1 (de) Halbsynthese von paclitaxel mit hilfe von dialkyldichlorsilanen
WO2001022951A3 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
ATE58135T1 (de) 1,3-oxathianderivate.
DE69624459D1 (de) Kondensierte indan-derivate und ihre salze
EP1445262A4 (de) Peptidderivat, pharmazeutisch unbedenkliches salz davon, verfahren zu dessen herstellung und dessen verwendung
EP0260605A3 (en) Dihydropyridine-5-phosphonic acid cyclic ester

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0975597

Country of ref document: EP